Moderna Advances Ebola Vaccine Candidate Toward Phase 2/3 Study

12:06 PM EST, 11/04/2026 (MT Newswires) -- Moderna (MRNA) will advance its investigational mRNA-1469 vaccine candidate against Bundibugyo ebolavirus toward a phase 2/3 efficacy study in the Democratic Republic of the Congo, subject to regulatory approval, following a recommendation from the World Health Organization's technical advisory group, the company said Wednesday. The vaccine candidate was recommended for inclusion in the study following encouraging preclinical and phase 1 clinical results. The phase 2/3 study will be conducted as part of the DRC's response to the Bundibugyo virus disease outbreak, the company added. Moderna is developing mRNA-1469 under an expanded collaboration with the Coalition for Epidemic Preparedness Innovations, according to the statement. Price: 249.86, Change: +21.42, Percent Change: +9.38